Application of protoMASC(TM), a biologically optimised protein PEGylation technology, in cancer vaccination

Proceedings of the Controlled Release Society

Volumn , Issue 26, 1999, Pages 661-662

  Wright, L C ^a   Gardiner, A ^a   Malik, F ^a   Galea Lauri, J ^a   Delgado, C ^a   Neale, D ^a   Fisher, D ^a   Buckley, R G ^a   Kippen, A D ^a   Farzaneh, F ^a   Francis, G E ^a  

^a PolyMASC Pharmaceuticals plc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; INTERLEUKIN 2; MACROGOL;

ANIMAL CELL; ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GENETIC ENGINEERING; HYDROGEL; MELANOMA; MOUSE; NONHUMAN; TUMOR GROWTH; VACCINATION;

EID: 0032760019     PISSN: 10220178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)